Cytocentrics receives GLP certification
Cytocentrics' customers are pharmaceutical companies that wish to avoid undesired side effects of pharmaceutical ingredients with human ion channels. This type of testing is required by the EMEA, the European regulatory authority for pharmaceutical drugs as well as its US counterpart, the FDA. These authorities' regulations stipulate that all non-clinical trials must be carried out under the GLP guidelines. "This serves to clarify side effects of substances before they are administered to people", explained Dr. Thomas Knott, board member and founder of Cytocentrics AG.
Cytocentrics AG is now authorized to perform one part of this pre-clinical testing specific for the effects of pharmaceutical substances on human ion channels as a service provider. "One unique aspect of our certification is that our automated patch clamp technology, called CytoPatch(TM), has been approved in addition to the conventional patch clamp method. This technology has been in-house at Cytocentrics," commented Dr. Knott.
Most read news
Organizations
Other news from the department politics & laws
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.